Literature DB >> 16273603

Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats.

Bing Tan1, Jie-Fei Huang, Qun Wei, Hong Zhang, Run-Zhou Ni.   

Abstract

AIM: To study the anti-hepatoma efficiency of arsenic trioxide (As(2)O(3)) in the treatment of experimental rat hepatocellular carcinoma (HCC) induced by 2-acetamidofluorene (2-FAA) and to elucidate the possible mechanisms.
METHODS: SD rats (2 mo old) had been fed with 2-FAA for 8 wk to induce HCC, and then they were treated with As(2)O(3) or matrine. On d 29, the rats were killed and the liver was weighed and liver tumors were counted. The histological changes of liver tissue were observed under microscope, and the cellular dynamic parameters were studied by flow cytometry. Immunohistochemistry (two-step method) was used to observe the expression of vascular endothelial growth factor (VEGF) and micro-vessel density (MVD) on consecutive sections. The pathological parameters were also analyzed, the levels of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBi), and direct bilirubin (DBi).
RESULTS: The number of liver tumors decreased significantly in groups treated with As(2)O(3), especially in medium-dose (1 mg/kg) group (t = 2.80, P<0.01). As(2)O(3) caused HCC cell death via apoptosis; necrosis was seen and apoptosis was common when the dose was 1 mg/kg. Proliferation index decreased sharply in medium-dose (1 mg/kg) group (7.87+/-4.11 vs 24.46+/-6.49, t = 2087, P<0.01), but not in 0.2 mg/kg group. However, S-phase fraction decreased dramatically in both groups, it reached the bottom level only when the dose was 1 mg/kg compared with control (0.40+/-0.13 vs 3.01+/-0.51, t = 2.97, P<0.01), and it was obviously accompanied with accumulation of cells in G(0)/G(1) (G(0)/G(1) restriction). The expressions of VEGF and MVD in medium-dose (1 mg/kg) group were significantly lower than normal saline group (0.63+/-0.74 vs 2.44+/-0.88, P<0.05; 15.75+/-3.99 vs 47.44+/-13.41, t = 2.80, P<0.01). Compared with normal saline group, medium- and low-dose groups As(2)O(3) and matrine lowered the levels of ALT in serum (61.46+/-9.46, 63.75+/-20.40, 61.18+/-13.00 vs 108.98+/-29.86, t = 2.14, P<0.05), but had no effect on the level of serum AST, TBi, and DBi.
CONCLUSION: As(2)O(3) had inhibitory effect on growth of experimental HCC in rats induced by 2-FAA, but had no obvious effect on normal hepatic cells. The mechanisms may involve decrease of cell division, accumulation of cells in G(0)/G(1) phase, apoptosis of tumor cells, and inhibitory effect on angiogenesis through blocking VEGF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273603      PMCID: PMC4436714          DOI: 10.3748/wjg.v11.i38.5938

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  8 in total

1.  The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells.

Authors:  Z Y Shen; J Shen; W J Cai; C Hong; M H Zheng
Journal:  Int J Mol Med       Date:  2000-02       Impact factor: 4.101

2.  Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.

Authors:  J Dai; R S Weinberg; S Waxman; Y Jing
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

Review 3.  Gene therapy strategies for tumor antiangiogenesis.

Authors:  H L Kong; R G Crystal
Journal:  J Natl Cancer Inst       Date:  1998-02-18       Impact factor: 13.506

4.  Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA.

Authors:  Jae-Ho Lee; Ja-Lok Ku; Young Jin Park; Kuhn-Uk Lee; Woo-Ho Kim; Jae-Gahb Park
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

5.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

6.  Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.

Authors:  I O Ng; R T Poon; J M Lee; S T Fan; M Ng; W K Tso
Journal:  Am J Clin Pathol       Date:  2001-12       Impact factor: 2.493

7.  Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.

Authors:  E K Manesis; G Giannoulis; P Zoumboulis; I Vafiadou; S J Hadziyannis
Journal:  Hepatology       Date:  1995-06       Impact factor: 17.425

8.  Phase II study of flutamide in the treatment of hepatocellular carcinoma.

Authors:  Y Chao; W K Chan; Y S Huang; H C Teng; S S Wang; W Y Lui; J Whang-Peng; S D Lee
Journal:  Cancer       Date:  1996-02-15       Impact factor: 6.860

  8 in total
  7 in total

1.  Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

Authors:  Jennifer Wu; Charles Henderson; Lynn Feun; Peter Van Veldhuizen; Philip Gold; Hui Zheng; Theresa Ryan; Lawrence S Blaszkowsky; Haobin Chen; Max Costa; Barry Rosenzweig; MaryLynn Nierodzik; Howard Hochster; Franco Muggia; Giovanni Abbadessa; Jonathan Lewis; Andrew X Zhu
Journal:  Invest New Drugs       Date:  2009-06-30       Impact factor: 3.850

2.  Induced differentiation of hepatocellular carcinoma by natural products.

Authors:  Xiong-Zhi Wu; Guang-Ru Xie
Journal:  Afr J Tradit Complement Altern Med       Date:  2008-06-18

3.  Arsenic trioxide-loaded CalliSpheres: In vitro study of drug release and antitumor activity, and in vivo study of pharmacokinetics, treatment efficacy and safety in liver cancer.

Authors:  Xuhua Duan; Guorui Zhao; Xinwei Han; Jianzhuang Ren; Hao Li; Pengfei Chen; Manzhou Wang; Shuguang Ju
Journal:  Oncol Rep       Date:  2021-05-13       Impact factor: 3.906

4.  Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intraarterial versus intravenous administration.

Authors:  Nak Jong Seong; Chang Jin Yoon; Sung-Gwon Kang; Jin Wook Chung; Hyo-Cheol Kim; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2012-03-07       Impact factor: 3.500

Review 5.  Chinese medicines induce cell death: the molecular and cellular mechanisms for cancer therapy.

Authors:  Xuanbin Wang; Yibin Feng; Ning Wang; Fan Cheung; Hor Yue Tan; Sen Zhong; Charlie Li; Seiichi Kobayashi
Journal:  Biomed Res Int       Date:  2014-10-14       Impact factor: 3.411

6.  Evaluation on Efficacy and Safety of Arsenic Trioxide Plus Transcatheter Arterial Chemoembolization Versus Transcatheter Arterial Chemoembolization alone forzzm321990Unresectable Primary Liver Cancer

Authors:  Haitao Yang; Sijing Zhou; Ruifen Shen; Shuimei Luo; Lina Li; Heng Lin; Huijuan Chen; Ziyuan Liao; Wanzun Lin; Xianhe Xie
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26

7.  Hepatic Arterial Chemoembolization With Arsenic Trioxide Eluting CalliSpheres Microspheres Versus Lipiodol Emulsion: Pharmacokinetics And Intratumoral Concentration In A Rabbit Liver Tumor Model.

Authors:  Xu-Hua Duan; Hao Li; Jian-Zhuang Ren; Xin-Wei Han; Peng-Fei Chen; Feng-Yao Li; Guo-Hao Huang; Shu-Guang Ju
Journal:  Cancer Manag Res       Date:  2019-11-26       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.